Glaucoma is a leading cause of irreversible blindness, affecting over 60 million people worldwide.

Medications to increase uveoscleral outflow:

- Prostaglandin analogs

- Alpha agonists

Medications to decrease aqueous humor production:

- Beta-blockers

- Carbonic anhydrase inhibitors

- Alpha agonists

The FDA approved netarsudil ophthalmic solution (0.02%) in December 2017. It is indicated to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Netarsudil does not yet have any non-FDA-approved indications. The European Medicines Agency approved netarsudil in 2019. Netarsudil is available as a 0.02% ophthalmic solution for once-daily topical application.